Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 28, 2025--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360 ® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer.
Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution, potentially enabling a new era of precision oncology research and clinical applications.
In addition, since Guardant360 Tissue is built on the smart liquid biopsy platform, it requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tumor tissue samples from patients failed to meet the surface area requirement – meaning those patients couldn't qualify for testing. 1 The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue.
'Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling a much broader dimension of insights to provide biopharma and oncologists with an unprecedented view of each individual tumor,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'And because it is built on our smart liquid biopsy platform, the test will leverage the countless multiomic applications that are being built around our Guardant360 liquid biopsy ecosystem. We believe this synergy will provide a new level of clinical actionability and improved patient outcomes across our entire product portfolio.'
For biopharmaceutical partners, the Guardant360 Tissue test offers differentiated molecular profiling by its extensive and unique genomic and epigenomic offering. The test analyzes 742 DNA genes and fusions in 367 RNA genes, with the ability to provide exome-wide analysis of the tumor methylome.
Test results are available in less than two weeks. Guardant360 Tissue is covered by Medicare for eligible patients.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
References
1. Tomlins, Scott A et al. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology. 2021.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250428299929/en/
CONTACT: Investor Contact:
Zarak Khurshid
[email protected] Contact:
Michael Weist
[email protected]
+1 317-371-0035
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Guardant Health, Inc.
Copyright Business Wire 2025.
PUB: 04/28/2025 08:05 AM/DISC: 04/28/2025 08:04 AM
http://www.businesswire.com/news/home/20250428299929/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
23 minutes ago
- Business Upturn
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On May 28, 2025, before the market opened, published an article entitled 'Tempus AI stock sinks following Spruce Point short report.' The article stated Tempus AI shares had fallen after 'the company was targeted in a short-seller report by Spruce Point. The report raised serious concerns about the integrity of Tempus AI's product, the credibility of its management, and its financial reporting practices.' On this news, Tempus AI's stock fell 19.2% on May 28, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Miami Herald
2 hours ago
- Miami Herald
Legendary fund manager sends blunt 6-word message on bitcoin
It's been a wild ride for markets since President Trump announced widespread tariffs on April 2. Trump's so-called "Liberation Day" announcement included higher tariff rates than hoped, leading to investors reworking their expectations for the U.S. economy. There's evidence that a potential U.S. economic slowdown may already be underway, and despite ongoing tariff negotiations, risks remain that tariffs may push the economy into stagflation or outright recession. That risk continues to cast a shadow over risk assets, including stocks and cryptocurrency, which tend to perform best when wallets are fat and consumers and businesses are increasing spending, rather than ratcheting back. Related: President Trump sends harsh message to Federal Reserve on interest rate cuts The stock market sell-off was big, with the S&P 500 and Nasdaq Composite falling 19% and 24% from early-year highs, respectively. Bitcoin fell alongside stocks, losing 27% from its January high through April 8. The drop in risk assets was unsettling, but created opportunity for risk-tolerant investors to 'buy the dip.' Since President Trump paused most of the reciprocal tariffs announced on April 2 on April 9, the Nasdaq and bitcoin have surged higher by 28% and 39% respectively. The gains have been impressive, but not everyone is convinced it will be clear sailing from here. Veteran Wall Street bond manager Bill Gross has navigated good and bad markets since 1971. He co-founded Pacific Investment Management Co., or PIMCO, a huge firm with $2 trillion under management. He formerly managed over $270 billion via PIMCO's Total Return Fund, earning him the "Bond King" nickname before moving to Janus Henderson Investors from 2014 to 2019. Gross offered a blunt message about bitcoin this week, and given his track record, his opinion is worth considering. Image source: Bloomberg/Getty Images There's been considerable debate about what will happen to the economy next. Many think tariffs will tax cash-strapped consumers later this year, lowering economic growth, even as businesses press pause on projects awaiting trade deal clarity. Others believe the risks of tariffs derailing activity are overblown and temporary. The jobs market arguably remains healthy, given that the unemployment rate is relatively low at 4.2%. However, unemployment is up from 3.4% in 2023, and companies announced 93,816 job cuts in May, up 47% year over year, according to Challenger, Grey, & Christmas. Related: Analyst resets stocks, gold outlook after rally The uptick in joblessness prompted the Federal Reserve to cut interest rates by 1% last year; however, the Fed has paused on additional cuts over fear that reducing rates could swell inflation, given that tariffs are only beginning to be felt on prices. The Fed's hesitancy to cut interest rates has drawn sharp criticism from the White House, ostensibly because it recognizes tariffs may slow GDP, worsening unemployment. If the economy were to drop off, and the Fed remained unwilling to budge on interest rates, Congress may be unable to adjust fiscal policy fast enough to bridge the gap, given our deficit and mountain of debt. The U.S. deficit is over $1.8 trillion, representing roughly 6.4% of gross domestic product. Meanwhile, total public debt outstanding is approximately 122% of GDP, far higher than its 75% level in 2008 during the Great Recession. The economic uncertainty has led to bitcoin and gold finding willing buyers as market participants look to diversify risk. Bill Gross's 50 years of Wall Street experience mean he's seen many market pops and drops, including the Nifty 50, skyrocketing inflation in the 1970s, the S&L crisis in the late 80s and early 90s, the Internet boom and bust, the Great Recession, Covid, and the 2002 bear market. More Experts Fed official sends strong message about interest-rate cutsBillionaire fund manager sends surprising message on trade deficitHedge-fund manager sees U.S. becoming Greece In short, Gross has been around the block, making his take on bitcoin worth paying attention to. Gross believes bitcoin is valuable because individuals and others widely hold it, and its supply is capped. "There are now approximately 19.4 million Bitcoins priced at about 107,000 each. The supply of total coins is capped at 21 million over the next few years of "mining," wrote Gross recently on X. "While hard to estimate, approximately 90-95% are held by individuals, institutions, and the moment there is "value" to a Bitcoin." However, Gross appears to think that bitcoin's value may be reflected in its price after its recent rally. "It is in the "meme stock" world for the most part - more valuable than a Trump coin but subject to excessive volatility with underlying value hard to measure," wrote Gross. "There are better risk/reward opportunities," added Gross bluntly. "Any asset category using high leverage is a future risk not only to the asset itself but to the financial system as a whole." Related: Veteran fund manager resets stock market forecast amid Musk, Trump fallout The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
2 hours ago
- Yahoo
Why Plug Power Stock Popped Today
Plug Power wants authority to issue more shares. Either that, or it wants to conduct a reverse stock split. If shareholders let it do the first thing, it might be able to avoid doing the second thing. 10 stocks we like better than Plug Power › Shares of Plug Power (NASDAQ: PLUG), the maker of fuel cell systems -- and now also of the hydrogen to fuel them -- shot 13% higher through 1:11 p.m. ET Friday, as investors received encouragement that the company might be able to avoid a devastating (to morale) reverse stock split. Our story begins one week ago, when Plug Power sent shareholders a preliminary proxy statement advising of the matters that will be raised at its July 3 annual general meeting: "Approval of an amendment to the Company's charter to increase the number of authorized shares of the Company's common stock from 1,500,000,000 shares to 3,000,000,000 shares;" and "Approval of ... a reverse stock split ... at a ratio of not less than 1-for-5 and not more than 1-for-200." Unable to earn a profit selling fuel cells or hydrogen, Plug Power has to continually create and sell new shares to keep itself solvent. But as its share count approaches 1.1 billion, the company will soon need to authorize more shares to keep this ball rolling. Either that, or it must shrink its share count through a reverse split -- and then resume growing the share count again. As a business model, this all leaves much to be desired. I certainly wouldn't invest in Plug Power myself. But as points out today, Plug is pleading with investors to approve at least one of the above options so that it can remain in business. As a consolation prize, Plug is also assuring investors that if they raise the ceiling on shares outstanding, it can avoid the reverse-split option. Investors seem encouraged by this assurance today. That's why they're bidding Plug stock up. Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Plug Power Stock Popped Today was originally published by The Motley Fool
